Gene expression profiling of pediatric acute myelogenous leukemia.
暂无分享,去创建一个
J. Downing | W. Williams | R. Mahfouz | S. Raimondi | Cheng Cheng | Xiaodong Zhou | C. Pui | Jing Ma | D. Liang | L. Shih | Guangchun Song | Kevin Girtman | Hsi-Che Liu | J. Rubnitz | S. Pounds | M. Onciu | S. Shurtleff | Raul C. Ribeiro | Mary E Ross
[1] M. Coleman,et al. Survival from cancer of the uterus in England and Wales up to 2001 , 2008, British Journal of Cancer.
[2] Cheng Cheng,et al. Improving false discovery rate estimation , 2004, Bioinform..
[3] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[4] Chi Wai So,et al. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. , 2004, Blood.
[5] R. Tibshirani,et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.
[6] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Arndt Borkhardt,et al. Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization , 2004, Molecular and Cellular Biology.
[8] Chen-An Tsai,et al. Estimation of False Discovery Rates in Multiple Testing: Application to Gene Microarray Data , 2003, Biometrics.
[9] Hyung-Lae Kim,et al. Comparison of oligonucleotide-microarray and serial analysis of gene expression (SAGE) in transcript profiling analysis of megakaryocytes derived from CD34+ cells , 2003, Experimental & Molecular Medicine.
[10] David A. Williams,et al. Hematopoietic Cell Regulation by Rac1 and Rac2 Guanosine Triphosphatases , 2003, Science.
[11] J. Downing,et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.
[12] Y. Hayashi,et al. AML1/RUNX1 mutations are infrequent, but related to AML‐M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies , 2003, Genes, chromosomes & cancer.
[13] Misao Ohki,et al. Identification of a gene expression signature associated with pediatric AML prognosis. , 2003, Blood.
[14] W. Hiddemann,et al. Molecular characterization of acute leukemias by use of microarray technology , 2003, Genes, chromosomes & cancer.
[15] S. Armstrong,et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. , 2003, Blood.
[16] T. Dingermann,et al. MLL-mediated transcriptional gene regulation investigated by gene expression profiling , 2003, Oncogene.
[17] G. Getz,et al. Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] T. A. Lister,et al. Genome‐wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation‐mediated fusion events , 2003, Genes, chromosomes & cancer.
[19] J. Downing,et al. Acute leukemia: a pediatric perspective. , 2002, Cancer cell.
[20] Zhijian Qian,et al. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] Deo Kumar Srivastava,et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Latchman,et al. The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21CIP1/Waf1 , 2002, Oncogene.
[23] Jeong-Sun Seo,et al. Gene Expression Profile of Megakaryocytes from Human Cord Blood CD34+ Cells Ex Vivo Expanded by Thrombopoietin , 2002, Stem cells.
[24] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[25] R. Eils,et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Gilliland,et al. Focus on acute leukemias. , 2002, Cancer cell.
[27] J. Downing,et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[29] F. Behm,et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. , 2001, Blood.
[30] S. Raimondi,et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Ringnér,et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.
[32] F. Berthold,et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Svaldi,et al. Simultaneous occurrence of bcr-abl and inv16 in a case of M1 acute myeloid leukemia , 2001, Leukemia.
[34] M. Caligiuri,et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] S. Raimondi,et al. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects , 2000, Leukemia.
[36] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[37] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[38] John M. Maris,et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.
[39] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[40] T. Naoe,et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.
[41] M. Siimes,et al. A population‐based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome , 1996 .
[42] J. Buckley,et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.
[43] R. Braziel,et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. , 1995, Blood.
[44] A. Morley,et al. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. , 1994, Leukemia.
[45] M. Caligiuri,et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. , 1994, Cancer research.
[46] M. Caligiuri,et al. ALL-1 partial duplication in acute leukemia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] Y. Hayashi,et al. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. , 1994, Cancer research.
[48] M. Caligiuri,et al. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. , 1994, Cancer research.
[49] P. Fenaux,et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .
[50] T. Naoe,et al. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia , 1993 .
[51] F. Behm,et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. , 1992, Blood.
[52] H. Dombret,et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. , 1992, Blood.
[53] K. Umesono,et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.
[54] Christine Chomienne,et al. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.
[55] H. Gralnick,et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.
[56] E. Dmitrovsky,et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.
[57] A. Meloni,et al. t(16;21)(p11.2;q22): a recurrent primary rearrangement in ANLL. , 1991, Cancer genetics and cytogenetics.
[58] N. Kamada,et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. , 1991, Blood.
[59] Christine Chomienne,et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.
[60] J. Radich,et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. , 1990, Blood.
[61] F. Behm,et al. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] D. Catovsky,et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[63] B. Efron,et al. A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .
[64] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[65] Nathan Mantel,et al. Chi-square tests with one degree of freedom , 1963 .
[66] M. Yao,et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23 , 2002, Leukemia.
[67] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[68] E. Lander,et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.
[69] P. Perrotta,et al. From www.bloodjournal.org by on April 14, 2008. For personal use only. , 2002 .
[70] J. Buckley,et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.
[72] D. Grimwade,et al. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia. , 1997, Current topics in microbiology and immunology.
[73] G. Gustafsson,et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). , 1996, British journal of haematology.
[74] J. Rowley,et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. , 1995, Leukemia.
[75] M. Schell,et al. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. , 1992, Leukemia.
[76] 麻生 博也. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation , 1992 .
[77] P. John. Statistical Design and Analysis of Experiments , 1971 .
[78] P. Pandolfi,et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor a locus (leukemogenesis/rearrangements) , 2022 .